As per the terms of the agreement, Eisai is expected to get exclusive worldwide rights (excluding some countries) for the development and commercialization o f compound as well as pharmaceutical products that contain the compound as an active ingredient for the treatment of solid tumors and leukemia, with the right to sublicense from PRISM.
Additionally, PRISM will also give the option to Eisai to acquire the exclusive worldwide rights (excluding some countries) for the development and commercialization of analogous compounds of the CBP/ß-catenin inhibitor and pharmaceutical products that contain analogous compounds as an active ingredient for the treatment of solid tumors and leukemia, with the right to sublicense.